losartan / Generic mfg. - LARVOL DELTA

Inferior vena cava agenesis presenting as iliofemoral deep vein thrombosis in a 49-year-old male (ASH 2025) - "Case Presentation We present the case of a 49-year-old man with a past medical history of hypertension managed with losartan and impaired glucose tolerance treated with metformin...He was started on enoxaparin and later transitioned to rivaroxaban for outpatient anticoagulation...Conclusion This case underscores the diagnostic and therapeutic challenges in managing iliofemoral DVT due to IVC agenesis. Early identification and intervention can lead to favorable outcomes, particularly with the use of endovascular techniques and comprehensive follow-up."

Cardiovascular • CNS Disorders • Developmental Disorders • Hematological Disorders • Hypertension • Thrombosis • Venous Thromboembolism

Targeting hemolysis and raas: Osivelotor and losartan ameliorate sickle cell renal pathology (ASH 2025) - "Osivelotor (GBT021601), a second-generation inhibitor of sickle hemoglobin (Hb)polymerization, shares a mechanism with voxelotor, but has improved pharmacokinetics. The combination treatment led tothe greatest improvement across functional, molecular and structural indicators of kidney damage. Thesefindings suggest that co-targeting hemolytic and RAAS pathways addresses the multifactorial nature ofSCD nephropathy, offering a potentially synergistic therapeutic strategy."

Cardiovascular • Fibrosis • Genetic Disorders • Hematological Disorders • Hypertension • Immunology • Nephrology • Renal Disease • Sickle Cell Disease • CST3 • KIM1

Renin-angiotensin-aldosterone system inhibitors exacerbate anemia in sickle cell disease (ASH 2025) - "Hb, Epo concentrations, and reticulocyte % werecompared by RAASi using ANOVA adjusting for age, sex, SCD genotype, estimated glomerular filtrationrate (eGFR), and hydroxyurea (HU)...No difference inreticulocyte % was observed (P=0.3).Transgenic SCD mice: Losartan treatment led to significantly lower Hb concentrations after 6-weeks (β -1.9 ±0.41g/dL; P=0.0002) and 14-weeks (β -2.0 ±0.34g/dL; P<0.0001) compared to untreated mice,adjusting for sex... Cross-sectional: The median age of the Walk-PHaSST cohort was 36 (interquartile range [IQR] 25–47)years, 346 (53%) were female, 501 ](76%) were Hb SS/Sβ0 genotype, 245 (37%) were on HU, and themedian eGFR was 117 (IQR, 93–129) mL/min/1.73m2. Those on RAASi (n=58) were older (42 vs 35 years; P=0.002) and had a lower eGFR (117 vs 100 mL/min/1.73m2; P<0.0001). RAASi use was independentlyassociated with lower Hb concentrations (β -0.44 ±0.21; P=0.039) after adjusting for age, sex, HU, eGFR,and SCD genotype;..."

Anemia • Diabetes • Genetic Disorders • Hematological Disorders • Metabolic Disorders • Renal Disease • Sickle Cell Disease

Clinical Outcomes of Rose Bengal Photodynamic Therapy for Severe Infectious Keratitis. (PubMed, Cornea) - "RB-PDT shows potential as an adjuvant therapy for managing severe infectious keratitis. TPK was avoided in 61.9% of cases."

Clinical data • Journal • Diabetes • Keratitis • Metabolic Disorders • Ocular Infections • Ocular Inflammation • Ophthalmology • Transplantation

A systematic review of commencing full dose antihypertensives in newly diagnosed hypertension. (PubMed, Blood Press) - "The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. The review indicates that initiating full dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited and further RCTs are required to assess this in specific patient groups to assess safety and efficacy."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hypertension • Nephrology • Renal Disease

MYOFLAME-19: Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19 (clinicaltrials.gov) - P3 | N=279 | Active, not recruiting | Sponsor: Valentina Puentmann | Trial completion date: Dec 2028 ➔ Mar 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease • Inflammation • Novel Coronavirus Disease

Therapeutic Targeting of Epithelial Mesenchymal Cellular Plasticity in Pancreatic Cancer. (PubMed, Clin Cancer Res) - P2 | "GSK-3b blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor suppressive immune microenvironment."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • CD8 • CEACAM6 • FN1 • TGFB1

Risk Factors for Drug-Induced Severe Cutaneous Adverse Reactions: A Real-World Pharmacovigilance Analysis. (PubMed, J Dermatol) - "Logistic regression identified older age, male sex, and 114 drugs as independent risk factors for drug-induced SCARs, including amlodipine (adjusted ROR = 2.89), bisoprolol (adjusted ROR = 3.52), and losartan (adjusted ROR = 2.77). In the non-Asian population, the strongest signals were observed for allopurinol (adjusted ROR = 98.52), cefotaxime (adjusted ROR = 68.52), and lamotrigine (adjusted ROR = 38.59), whereas apalutamide (adjusted ROR = 14.57), ipilimumab (adjusted ROR = 3.24), and acetylsalicylic acid (adjusted ROR = 2.85) were detected only in Asians...The Asian population had a significantly shorter TTO compared to the non-Asian population (p < 0.001). This study uses FAERS data to analyze risk factors for drug-induced SCARs, emphasizing early identification and discontinuation of suspected drugs to enhance patient safety."

Adverse events • Journal • Real-world evidence • Immunology

Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the 'MOI-A' study; a randomised, phase 2/pilot, dose-escalating trial. (PubMed, BMJ Open) - "Sheffield Children's National Health Service Foundation Trust (UK) and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Ortopedico Rizzoli (Italy) are the joint study sponsors. ISRCTN (ISRCTN13317811)."

Biomarker • Journal • P2 data • Fatigue • Genetic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Otorhinolaryngology • Pain • Sarcopenia

Losartan and Paclitaxel in PROC (clinicaltrials.gov) - P2 | N=27 | Not yet recruiting | Sponsor: Massachusetts General Hospital

New P2 trial • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study (clinicaltrials.gov) - P=N/A | N=13656 | Not yet recruiting | Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

New trial • Real-world evidence • Cardiovascular • Infectious Disease • Pneumonia • Respiratory Diseases

Vision rehabilitation of post-Descemet membrane endothelial keratoplasty Pseudomonas keratitis utilizing losartan ophthalmic solution and scleral contact lens: a case report. (PubMed, J Med Case Rep) - "The present report emphasizes the efficacy of personalized therapeutic strategies in the postoperative management of Descemet membrane endothelial keratoplasty patients, highlighting innovative pharmacological approaches and customized scleral contact lenses in addressing complications and enhancing patient outcomes."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Transplantation

Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials. (PubMed, BMC Cardiovasc Disord) - "Based on the only available eligible evidence, the combination of losartan and amlodipine was the optimal dual therapy for Chinese patients with hypertension and hyperuricemia, while allisartan and losartan were the most effective monotherapies for lowering serum uric acid. These findings are not generalizable to non-Chinese populations, reflecting a gap in global evidence rather than intentional study scope restriction."

Journal • Retrospective data • Review • Cardiovascular • Hypertension

L-Borneol ameliorates renal fibrosis induced by unilateral ureteral obstruction in rats. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "BO may represent a promising therapeutic candidate for RF associated with chronic kidney disease (CKD). Nevertheless, the potential toxicities observed with higher doses warrant further investigation into the underlying molecular mechanisms and clinical efficacy."

Journal • Preclinical • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Oncology • Renal Disease • AMPK • CAT • IL17A • MAPK8 • TNFA

Multisystem Complications and Therapeutic Trends in Scleroderma Renal Crisis: Insight from a Five-Year Retrospective Cohort Study (KIDNEY WEEK 2025) - "Renal: Acute renal failure in 12.0% ESRD in 2.8%, renal transplant in 0.7%, Hemodilaysis in 2.1%, Cardiovascular: NSTEMI in 2.8%, STEMI in 0.8%, Neurological: Stroke in 2.3%, Pulmonary: Edema in 2.4%, Pulmonary Hypertension in 16.8%, Pulmonary fibrosis in 7.3%, Treatment: Antihypertensives: ACEi (Captopril in 2.4%, enalapril in 1.2%, and ARBs: Losartan in 5.6%, valsartan in 2.4%). Immune suppressants: Hydroxychloroquine (HCQ) in 7.9%, methotrexate (MTX) in 3.7%, mycophenolate in 12.7%, rituximab in 4.1%, prednisone in 18.4%, methylprednisone in 18.3% of the cohort...Low utilization of ACEi and ARBs indicates potential therapeutic gaps. Further research to refine treatment strategies is essential to improve mortality and patient outcomes."

Retrospective data • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Hypertension • Immunology • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

Isatuximab for Refractory Primary FSGS (KIDNEY WEEK 2025) - "He achieved partial remission with steroids, tacrolimus, and mycophenolate mofetil (MMF), and eventually stabilized on prednisone and tacrolimus, with losartan, empagliflozin, spironolactone, and atorvastatin...After rituximab induction, UPCR was 3.14, albumin 3 g/dL...CD-38 targeting antibodies such as isatuximab have been studied in the treatment of immune-mediated diseases, including primary FSGS, demonstrating either total remission or improvement in disease severity in cases refractory to conventional therapies. Further research is needed to determine optimal treatment regimens and dosing frequency, better study their efficacy, and the potential risk of adverse effects."

Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Glomerulonephritis • Immunology • Nephrology • Renal Disease • Sarcoma

Role of Angiotensin Receptor Blockers on Cardiovascular Protection in Marfan Syndrome: A Literature Review. (PubMed, Health Sci Rep) - "Clinical trials highlighted losartan's ability to slow aortic root dilation in adults and children, with synergistic effects when combined with beta-blockers...ARBs show promise in mitigating cardiovascular complications in MFS by reducing aortic root dilation and improving vascular function. Further research is essential to determine optimal dosing, long-term efficacy, and combination therapy potential, paving the way for personalized management strategies to improve patient outcomes."

Journal • Cardiovascular • Genetic Disorders • Pediatrics • Rheumatology • TGFB1

Bioinformatics-based identification of RAS disequilibrium involved in post-hemorrhagic shock mesenteric lymph return-mediated acute kidney injury in mice. (PubMed, PeerJ) - "Subsequently, male C57BL/6 mice subjected to hemorrhagic shock were treated with the angiotensin converting enzyme (ACE) inhibitor enalapril, angiotensin (1-7) (Ang (1-7)), and angiotensin II (Ang II) type 1 receptor (AT1R) inhibitor losartan. Conversely, the beneficial role of MLDL was abolished by Ace2 deficiency and the administration of Ang II and A-779. Collectively, these findings indicate that disequilibrium between the ACE-AngII-AT1R and ACE2-Ang (1-7)-MasR axes is implicated in PHSML-mediated AKI."

Journal • Preclinical • Acute Kidney Injury • Hematological Disorders • Nephrology • Renal Disease • ACE2

A losartan-laden thermosensitive hydrogel scaffold to boost tumor chemo-immunotherapy via remodeling tumor mechanical microenvironment. (PubMed, Colloids Surf B Biointerfaces) - "Herein, we have meticulously developed a drug-sustained-release scaffold that contains three drug components of oxaliplatin, losartan, and immune checkpoint inhibitor (anti-PD-L1), structured with a thermosensitive hydrogel F127 that can gel in situ upon triggering at body temperature. The constructed F127@Oxpt-Los-aPDL1 scaffold triggers a potent anti-tumor immune response, achieving outstanding tumor suppression effects and even induces a powerful abscopal effect, effectively inhibiting the growth of distant tumors. This research presents a novel combination treatment strategy aimed at enhancing the efficacy of immune checkpoint inhibition therapy in stroma-rich tumors."

Journal • Oncology

Breast Cancer-Secreted DPP3 Promotes Lung Metastasis by Remodelling the Vascular Niche in Lung via the Rap1 Signalling Pathway. (PubMed, J Extracell Vesicles) - "Finally, treatment with losartan pharmacologically inhibits the ISGylation of DPP3, preventing its secretion via sEVs. In summary, our findings demonstrate that DPP3, which is encapsulated in sEVs and secreted by breast cancer cells, regulates angiogenesis in the lung and remodels vascular niches to promote breast cancer lung metastasis, making it a potential target for the diagnosis and treatment of breast cancer metastasis."

Journal • Breast Cancer • Oncology • Solid Tumor • PFKP • YBX1

Epidemiology and Risk Factors for Arthrofibrosis Following Total Knee Arthroplasty: Towards Effective Prevention. (PubMed, J Knee Surg) - "Prevention strategies focus on patient education, rehabilitation, and pharmacological interventions, with emerging evidence supporting the use of celecoxib, dexamethasone, COX-2 inhibitors, and losartan in reducing the risk of arthrofibrosis. Despite progress, gaps remain, particularly regarding standardized definitions and high-quality randomized controlled trials to assess the optimal treatment methods."

Journal • Orthopedics • Pain

Overcoming MRSA Antibiotic Resistance Through Losartan Repurposing with Carbon Dot-Conjugated Cerosomal Nanocarriers. (PubMed, Pharmaceutics) - "Histological evaluation supported improved healing in CD-CER-treated groups. Overall, CD-functionalized CERs offer a promising multifunctional nanoplatform for repurposing LOS as a topical therapeutic against MRSA-associated skin infections."

Journal • Dermatology • Infectious Disease

Curcumin in the Treatment of Kidney Disease: A Systematic Review with a Focus on Drug Interactions. (PubMed, Antioxidants (Basel)) - "The curcumin-drug interactions reviewed were: -piperine, -epigallocatechin gallate, -losartan, -ginkgolide B, -rosuvastatin, -insulin, -cilostazol, and -ginger. These interactions improve curcumin bioavailability, and synergistic anti-inflammatory/antioxidant/antifibrotic and renoprotective effects. Future research should prioritize large-scale clinical trials to evaluate the efficacy and safety of curcumin in diverse KD populations."

Journal • Review • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

Effects of Inhibitors of the Activity of the Circulating Renin-Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells. (PubMed, Int J Mol Sci) - "We then determined the effects of drugs that inhibit the action of renin (VTP-27999 and aliskiren) or angiotensin-converting enzyme (perindoprilat) or block the angiotensin II type 1 receptor (losartan and telmisartan). RAS inhibitors were most effective in Ishikawa cells, which had the highest levels of RAS expression. Therefore, levels of RAS expression in endometrial cancers might indicate the potential efficacy of RAS drugs."

Journal • Endometrial Cancer • Oncology • Solid Tumor

Brain AT1 and AT2 receptors and nitric oxide in baroreflex regulation of renal sympathetic activity in unanaesthetised rats. (PubMed, Sci Rep) - "Baroreflex gain curves (BRC) were generated following intracerebroventricular (I.C.V.) infusion of saline, Ang II, or Ang II combined with either losartan, PD123319 (AT2 antagonist), or L-NAME (NO synthase inhibitor)...By contrast, AT1 exerts an inhibitory effect on the baroreflex that is independent of NO. These observations suggest that targeting central AT2 receptors may represent a potential therapeutic strategy for conditions such as neurogenic hypertension, where impaired baroreflex function is present."

Journal • Preclinical • Cardiovascular • Hypertension